Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy

Fig. 5

Percentage apoptosis in ovarian cancer cells 7-days after azacitidine, carboplatin or combination azacitidine and carboplatin treatment in (A) all cell lines, (B) BRCA-wildtype cell lines, and (C) BRCA-mutant cell lines. Percentage apoptosis is represented as the mean ± SEM of triplicates of three independent experiments

Back to article page